Orgovyx (Relugolix)

Relugolix, the active ingredient in Orgovyx, is a gonadotropin-releasing hormone (GnRH) antagonist presented as a tablet for oral use. It is indicated for the treatment of advanced prostate cancer in men. GNH USA supplies Orgovyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

GNH USA supplies Orgovyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

Orgovyx is a GnRH antagonist that acts on the hormonal pathway driving prostate cancer growth.

- Advanced prostate cancer: Improves overall survival and delays disease progression. - Metastatic castration‑resistant prostate cancer: Provides hormonal control when combined with androgen‑targeted therapy. - Hormone‑sensitive prostate cancer: Used as part of initial hormonal therapy to achieve castration‑level testosterone suppression.

Orgovyx may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Hot flashes - Decreased libido - Fatigue - Headache - Diarrhea - Nausea

Serious or Rare Side Effects: - Cardiovascular events such as myocardial infarction or stroke - Severe allergic reactions (anaphylaxis) - Elevated liver enzymes - Bone fractures - Seizures - Severe hypertension

Before initiating therapy with Orgovyx, clinicians should evaluate patient history and monitor specific parameters.

- Cardiovascular assessment: Review history of heart disease, stroke, or hypertension. - Liver function: Check baseline hepatic enzymes and monitor periodically. - Bone health: Assess risk of fractures, especially in patients with osteoporosis. - Drug interactions: Review concomitant medications for potential interactions. - Pregnancy and lactation: Contraindicated in women; ensure effective contraception in men of reproductive potential. - Store at ambient temperature: Keep below 25°C, protect from moisture and direct light.

Orgovyx can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may reduce rel‑relugolix exposure. - Co‑administration with hormonal contraceptives may diminish efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin) may have altered INR values. - Antiepileptic drugs (e.g., carbamazepine) may affect plasma levels. - Proton pump inhibitors may modestly increase absorption. - Statins metabolized by CYP3A4 (e.g., simvastatin) may have increased exposure.